Eur J Cancer: A new model for identifying stage I/IIA melanomas with a high risk of recurrence

Complementary therapy can extend non-recurrence survival (RFS) in patients with stage III melanoma, so that the five-year melanoma-specific survival rate (MSS) for stage IIIA/B melanoma can reach 83-93%, similar to that of patients with stage IIB/C (82-87%).
currently, there are no signs of complementary treatment in patients with stage I/IIA skin melanoma (CM), even if the risk of recurrence in such patients is not yet clear.
, there is an urgent clinical need to identify diagnostic tools for high-risk I/IIA patients.
Eggermont and others have developed a model that combines clinical pathology and gene expression changes (CP-GEP) to help clinically identify patients with stage I/IIA melanomas with a high risk of recurrence.
the model's ability to identify sub-groups of high-risk patients was recently published in the journal European Journal of Cancer.
the overall survival prognostics of all patients, the analysis team included 837 primary CM patients to assess the predicted value of the CP-GEP model.
CP-GEP model combines breslow thickness with patient age, as well as the expression of eight genes in primary tumors.
addition, a special queue of 580 I/IIA patients was divided into the CP-GEP High Risk Group and the CP-GEP Low Risk Group based on their risk of recurrence.
the main endpoint of the study was five years of recurrence-free survival (RFS).
580 patients with special queues had a prognosis for survival in patients with stage I/IIA melanoma, CP-GEP-identified high-risk patients (47%) had five-year RFS below the low-risk group (74% vs 89%; HR 2.98, 95% CI 1.78-4.98, p-lt;0.0001).
in the subgroup of high-risk patients, relapse occurred more than in the first 3 years.
, the CP-GEP model can be used to screen patients with stage I/IIA melanomas with high risk of recurrence, who may benefit from complementary treatment.
。